Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834
Recruiting
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung cancer (ES-SCLC). The primary objectives of this study are to compare the effect of SG to SOC on objective response rate (ORR) as assessed by blinded independent central review (BICR) according to the Response Evaluation Criteria in Solid Tumors and to compare the effe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2025
Locations: Hope and Healing Cancer Services, Hinsdale, Illinois +69 locations
Conditions: Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Register for Updates
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
NCT06503614
Recruiting
This is a phase 2 open-label two cohort study of durvalumab plus monalizumab in patients with BCG-unresponsive or BCG-exposed CIS NMIBC. Arm A will enroll 43 participants who have cancer in situ (CIS) with or without high grade papillary urothelial cancer. Arm B will enroll 17 participants who do not have cancer in situ (CIS) but do have high grade papillary urothelial cancer. Eligible patients will be enrolled to receive up to 13 cycles of monthly combination of monalizumab and durvalumab. Both... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2025
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey +1 locations
Conditions: Non-muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma
Register for Updates
A Study of Observation and Follow-up in People With Basal Cell Carcinoma
NCT05473507
Recruiting
The purpose of this study is to find out more about how Basal Cell Carcimonas/BCCs grow and to learn more effective ways to monitor and treat these common cancers. This study will not provide any type of treatment for the participants' cancer; it is a 3-year observational study to monitor participants' cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2025
Locations: Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
Conditions: Basal Cell Carcinoma
Register for Updates
Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC
NCT06811909
Recruiting
This study examines a patient population with a non-healing, non-infected venous leg ulcer (VLU) having adequate arterial perfusion with confirmed venous reflux. It is hypothesized that weekly applications of the human placental allograft BioREtain® Amnion Chorion (BR-AC) applied to a non-healing VLU will result in a higher proportion of wounds showing complete healing within 12 weeks of initiating therapy, compared to standard care alone. This study has a crossover period, where subjects on st... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2025
Locations: Site 17, Guntersville, Alabama +20 locations
Conditions: Non-infected Venous Leg Ulcer, Venous Leg Ulcer, Venous Insufficiency, Venous Stasis, Venous Reflux
Register for Updates
Effectiveness Testing of a Videogame Intervention (No Baby No) to Decrease Contraception Non-use Among Adolescents.
NCT06990724
Recruiting
The purpose of this study is to evaluate the effectiveness of a videogame compared to an attention/time control at reducing contraceptive non-use among adolescents.
Gender:
ALL
Ages:
Between 15 years and 20 years
Trial Updated:
08/08/2025
Locations: Bronx Health Link, Bronx, New York +5 locations
Conditions: Contraceptive Usage, Contraception Behavior
Register for Updates
Once Weekly Infant Corticosteroid Trial for DMD
NCT05412394
Recruiting
The hypothesis tested here is that a lower dose of intermittent oral corticosteroids (5mg/kg/week) will be equally effective to the 10mg/kg/week dose.
Gender:
MALE
Ages:
Between 1 month and 30 months
Trial Updated:
08/08/2025
Locations: Lurie Children's Hospital of Chicago, Chicago, Illinois +3 locations
Conditions: Duchenne Muscular Dystrophy
Register for Updates
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109
Recruiting
Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma Kinase (ALK) positive, advanced Non-Small Cell Lung Cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2025
Locations: Palo Verde Hematology Oncology, Glendale, Arizona +6 locations
Conditions: Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
Register for Updates
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
NCT06513962
Recruiting
This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part of standard chemotherapy, but may cause damage to the ovaries. If the ovaries are not working well or completely shut down, then it will be difficult or impossible to get pregnant in the future. Triptorelin works by blocking certain hormones and causing the ovar... Read More
Gender:
FEMALE
Ages:
39 years and below
Trial Updated:
08/08/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +140 locations
Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Register for Updates
Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants
NCT07074327
Recruiting
The purpose of the study is to evaluate the effect of VX-407 on the pharmacokinetics of levonorgestrel (LNG) and ethinyl estradiol (EE), norgestimate (NGM) and EE, norethindrone (NET) and EE and drospirenone (DRSP) and EE. Also, to evaluate the safety and tolerability of co-administration of VX-407 with LNG/EE, NGM/EE, NET/EE and DRSP/EE.
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
08/08/2025
Locations: Altasciences - Kansas City, Overland Park, Kansas
Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Register for Updates
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT06806033
Recruiting
The main goal of this trial is to study the frequency and severity of cytokine release syndrome (CRS) in participants with diffuse large B-cell lymphoma (DLBCL) who are using a combination of glofitamab + gemcitabine + oxaliplatin (Glofit-GemOx) followed by glofitamab-only treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2025
Locations: Alaska Oncology & Hematology, LLC, Anchorage, Alaska +33 locations
Conditions: Diffuse Large B-Cell Lymphoma
Register for Updates
Listening to Calming Music
NCT06710886
Recruiting
The goal of this clinical trial is to explore possible benefits and mechanisms through which listening to music can improve health and wellness. The main goals of the study are: * To investigate whether pre-survey measures of autonomic reactivity relate to the overall functioning of participants. * To examine the immediate effects of listening to the augmented music. * To identify individual characteristics that influence the immediate effects of listening to the augmented music. Participants... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
08/08/2025
Locations: University of Florida McKnight Brain Institution, Gainesville, Florida +1 locations
Conditions: Music, Autonomic State
Register for Updates
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
NCT06909110
Recruiting
The primary purpose of this phase I/II study is to evaluate whether partially matched, ≥2/6 HLA-matched, viral specific T cells have efficacy against adenovirus, CMV, and EBV, in subjects who have previously received any type of allogeneic HCT or solid organ transplant (SOT), or have compromised immunity. Reconstitution of anti-viral immunity by donor-derived cytotoxic T lymphocytes has shown promise in preventing and treating infections with adenovirus, CMV, and EBV. However, the weeks taken to... Read More
Gender:
ALL
Ages:
Between 1 month and 65 years
Trial Updated:
08/08/2025
Locations: Jessie Alexander, Palo Alto, California +2 locations
Conditions: Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus Infections
Register for Updates